Probmet was founded in 2021 by a team of oncology researchers and biotech entrepreneurs driven by the urgent need for targeted therapies for brain metastases from breast cancer. Headquartered in Europe, the company brings together deep expertise in neuro-oncology, molecular biology, and drug development to create next-generation precision medicines. With support from leading cancer research institutions and early-stage biotech investors, Probmet is building a pipeline of therapies aimed at transforming treatment for patients suffering from this highly aggressive and underserved condition.